Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives.

Yanhui Wang, Zonghao Liang, Ziyang Liang, Wenfeng Lv, Min Chen, Yi Zhao

Journal: Journal of controlled release : official journal of the Controlled Release Society 2022;351():752-778

PMID: 36216173

Abstract

Prussian blue (PB) nanoparticles possess excellent physicochemical properties, including imaging features, robust photothermal conversion ability, catalytic activity, surface modifiability, effective drug loading, good stability, biocompatibility and biodegradability. With the advancement of nanotechnology, diverse PB-based nanoplatforms have been developed for biomedical applications. This review systematically summarized recent studies on PB-based nanoplatforms in the treatment of tumor (photothermal therapy, photodynamic therapy, chemotherapy, immunotherapy, theranostics, etc.), cardiovascular and cerebrovascular diseases (restenosis, atherosclerosis, thrombosis, ischemic stroke, etc.), bacterial infections (photothermal sterilization, biofilms disruption, etc.), and other inflammation-related diseases (liver injury, acute pancreatitis, inflammatory bowel disease, osteoarthritis, etc.). Finally, the existing challenges associated with current studies are discussed, and the future possible research and application directions for PB-based nanoplatforms are proposed, providing paradigms for subsequent development.

Copyright © 2022 Elsevier B.V. All rights reserved.

Address: School of Biomedical Engineering, Sun Yat-sen University, Shenzhen 518107, China.; School of Biomedical Engineering, Sun Yat-sen University, Shenzhen 518107, China. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.